WO2000051567A8 - Processes for making pharmaceutical oral ecb formulations and compositions - Google Patents

Processes for making pharmaceutical oral ecb formulations and compositions

Info

Publication number
WO2000051567A8
WO2000051567A8 PCT/US2000/005547 US0005547W WO0051567A8 WO 2000051567 A8 WO2000051567 A8 WO 2000051567A8 US 0005547 W US0005547 W US 0005547W WO 0051567 A8 WO0051567 A8 WO 0051567A8
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
ecb
compositions
processes
echinocandin
Prior art date
Application number
PCT/US2000/005547
Other languages
French (fr)
Other versions
WO2000051567A1 (en
Inventor
John Richard Schwier
Jerry Taylor
Original Assignee
Lilly Co Eli
John Richard Schwier
Jerry Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, John Richard Schwier, Jerry Taylor filed Critical Lilly Co Eli
Priority to AU33934/00A priority Critical patent/AU771727B2/en
Priority to CA002362482A priority patent/CA2362482A1/en
Priority to JP2000602036A priority patent/JP2002538097A/en
Priority to KR1020017011216A priority patent/KR20010112302A/en
Priority to BR0008713-0A priority patent/BR0008713A/en
Priority to EP00912160A priority patent/EP1156784A1/en
Priority to IL14518800A priority patent/IL145188A0/en
Publication of WO2000051567A1 publication Critical patent/WO2000051567A1/en
Priority to US09/942,435 priority patent/US6821951B2/en
Priority to HK02101824.8A priority patent/HK1040369A1/en
Publication of WO2000051567A8 publication Critical patent/WO2000051567A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A fluid bed spray process is described where one or more carbohydrates are incorporated into an echinocandin formulation to provide a significant improvement in thermal stability. The carbohydrate is solubilized with an echinocandin compound or echinocandin/carbohydrate complex in a solvent(s) to form a pharmaceutical solution which is sprayed onto the surface of a granular diluent or carrier. Alternatively, a granulating agent is added to the pharmaceutical solution which is then sprayed onto the surface of a non-granular diluent or carrier. The resulting granular oral formulations and medicaments derived therefrom are also described.
PCT/US2000/005547 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions WO2000051567A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU33934/00A AU771727B2 (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ECB formulations and compositions
CA002362482A CA2362482A1 (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions
JP2000602036A JP2002538097A (en) 1999-03-03 2000-03-02 Methods of making pharmaceutical oral ECB formulations and compositions
KR1020017011216A KR20010112302A (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions
BR0008713-0A BR0008713A (en) 1999-03-03 2000-03-02 Processes for preparing oral pharmaceutical formulations and compositions with ecb
EP00912160A EP1156784A1 (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions
IL14518800A IL145188A0 (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions
US09/942,435 US6821951B2 (en) 1999-03-03 2001-08-29 Processes for making pharmaceutical oral ECB formulations and compositions
HK02101824.8A HK1040369A1 (en) 1999-03-03 2002-03-11 Processes for making pharmaceutical oral ecb formulations and compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12269399P 1999-03-03 1999-03-03
US60/122,693 1999-03-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/942,435 Continuation US6821951B2 (en) 1999-03-03 2001-08-29 Processes for making pharmaceutical oral ECB formulations and compositions

Publications (2)

Publication Number Publication Date
WO2000051567A1 WO2000051567A1 (en) 2000-09-08
WO2000051567A8 true WO2000051567A8 (en) 2002-05-30

Family

ID=22404178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005547 WO2000051567A1 (en) 1999-03-03 2000-03-02 Processes for making pharmaceutical oral ecb formulations and compositions

Country Status (12)

Country Link
US (1) US6821951B2 (en)
EP (1) EP1156784A1 (en)
JP (1) JP2002538097A (en)
KR (1) KR20010112302A (en)
CN (1) CN1345230A (en)
AU (1) AU771727B2 (en)
BR (1) BR0008713A (en)
CA (1) CA2362482A1 (en)
HK (1) HK1040369A1 (en)
IL (1) IL145188A0 (en)
WO (1) WO2000051567A1 (en)
ZA (1) ZA200108001B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
ES2272096T3 (en) 1998-12-09 2007-04-16 Eli Lilly And Company PURIFICATION OF CYCLOPEPTIDIC COMPOUNDS OF EQUINOCANDINA.
JP4272359B2 (en) 1999-03-03 2009-06-03 イーライ リリー アンド カンパニー Echinocandin / Carbohydrate Complex
ATE338060T1 (en) 1999-03-03 2006-09-15 Lilly Co Eli FORMATION AND ANION EXCHANGE OF INNER CRYSTALLINE AMMONIUM SALTS OF ECHINOCANDIN B
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
IL145185A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Echinocandin pharmaceutical formulations containing micelle-forming surfactants
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20050233074A1 (en) * 2002-08-14 2005-10-20 Dalziel Sean M Solid flowable powder with high liquid loading
CA2490601C (en) * 2003-12-29 2006-05-02 Ferring B.V. Method for preparing solid dosage form of desmopressin
CA2865791C (en) 2011-03-03 2019-10-08 Cidara Therapeutics, Inc. Antifungal agents and uses thereof
LT3677252T (en) 2012-03-19 2023-10-10 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
CN103330932B (en) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 The pharmaceutical composition of a kind of MFG or its salt
EP3399995A4 (en) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
EP4268896A3 (en) 2016-03-16 2024-01-03 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CA3069423A1 (en) 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. Formulations for the treatment of fungal infections
CN109574811B (en) * 2018-11-22 2021-12-24 中山大学 Preparation method of anidulafungin side chain intermediate p-pentoxy terphenyl formic acid

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3293482A (en) 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (en) 1974-03-06 1976-09-29
US4299763A (en) 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4293483A (en) 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
US4293482A (en) 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4320052A (en) 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4293489A (en) 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4304716A (en) 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
US4876241A (en) 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
DK173802B1 (en) 1988-09-12 2001-11-05 Merck & Co Inc Preparation for the treatment of Pneumocystis carinii infections and use of a cyclohexapeptide for the preparation of a drug against Pneumocystis carinii infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US5202309A (en) 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JPH03240727A (en) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd Remedy for pneumocystosis-carinii pneumonia
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
IL98349A (en) 1990-06-07 1995-05-26 Lilly Co Eli Lipopeptide deacylase
IE912046A1 (en) 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
US5198421A (en) 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
JPH05271097A (en) 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd Aculeacin solubilizing agent and medicinal composition
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
TW264477B (en) 1992-03-19 1995-12-01 Lilly Co Eli
DE69232220D1 (en) 1992-09-22 2002-01-03 Takeo Takayanagi Carbohydrate complexes for the destruction of cancer cells
JPH06172205A (en) 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd Fat emulsifier containing acreasin compounds
US5383324A (en) 1993-04-23 1995-01-24 Baxter International Inc. Method for manufacturing and storing stable bicarbonate solutions
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5646111A (en) 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5629290A (en) 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US5786325A (en) 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5618787A (en) 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
CA2244238A1 (en) 1996-02-01 1997-08-07 Eli Lilly And Company Cyclic peptide antifungal agents
US5693611A (en) 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
CA2301184A1 (en) 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
EP0931834A3 (en) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin binding domain of 1,3-Beta-glucan synthase
US6323176B1 (en) 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000011023A2 (en) 1998-08-20 2000-03-02 Eli Lilly And Company Ring modified cyclic peptide analogs
AU763351B2 (en) 1998-08-28 2003-07-17 Eli Lilly And Company Reversible boronate complexes of 1,2-(cis)-diol cyclic-peptides
ES2272096T3 (en) 1998-12-09 2007-04-16 Eli Lilly And Company PURIFICATION OF CYCLOPEPTIDIC COMPOUNDS OF EQUINOCANDINA.
EP1140991A1 (en) 1998-12-16 2001-10-10 Eli Lilly And Company Cyclic peptide antifungal agents
AU2189500A (en) 1998-12-16 2000-07-03 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
JP4272359B2 (en) 1999-03-03 2009-06-03 イーライ リリー アンド カンパニー Echinocandin / Carbohydrate Complex
ATE338060T1 (en) 1999-03-03 2006-09-15 Lilly Co Eli FORMATION AND ANION EXCHANGE OF INNER CRYSTALLINE AMMONIUM SALTS OF ECHINOCANDIN B
IL145185A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Echinocandin pharmaceutical formulations containing micelle-forming surfactants
AU771727B2 (en) 1999-03-03 2004-04-01 Eli Lilly And Company Processes for making pharmaceutical oral ECB formulations and compositions
US6258821B1 (en) 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use

Also Published As

Publication number Publication date
AU3393400A (en) 2000-09-21
EP1156784A1 (en) 2001-11-28
US6821951B2 (en) 2004-11-23
HK1040369A1 (en) 2002-06-07
ZA200108001B (en) 2003-06-25
BR0008713A (en) 2001-12-26
KR20010112302A (en) 2001-12-20
IL145188A0 (en) 2002-06-30
CN1345230A (en) 2002-04-17
US20020151474A1 (en) 2002-10-17
CA2362482A1 (en) 2000-09-08
WO2000051567A1 (en) 2000-09-08
JP2002538097A (en) 2002-11-12
AU771727B2 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
WO2000051567A8 (en) Processes for making pharmaceutical oral ecb formulations and compositions
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
CA2311696A1 (en) Self-tanning composition comprising carmine
CA2386690A1 (en) Pharmaceutical tramadol salts
GEP20032967B (en) Indolyl-3-Glyoxylic Acid Derivatives As an Antitumor Agent and Pharmaceutical Composition
CA2311438A1 (en) Self-tanning mousse
WO2000027405A8 (en) Hyaluronic acid gel, process for the preparation thereof and medical materials containing the same
WO2002101412A3 (en) Spray freeze-dried compositions
WO2001032646A3 (en) Sulfonamide derivatives
AU2001293743A1 (en) Mechanically stable, liquid formulation washing, rinsing or cleaning agent doses
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
LT2000064A (en) Flash-melt oral dosage formulation
EP1040823A3 (en) Stable foam compositions
WO2001027109A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives
WO2001041742A3 (en) Antiviral medication
CA2356959A1 (en) Water-insoluble drug delivery system
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof
EP1059304A4 (en) Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
HUP0004386A3 (en) Methylenebisphosphonic acid derivatives, process for producing them and medicaments containing the same as active agent
BG106236A (en) Melt granulation
AU6308900A (en) Isoquinoline derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
CA2151561A1 (en) Hydrazino and hydroxyamino-14.beta.-hydroxyandrostane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805698.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 145188

Country of ref document: IL

Ref document number: 09942435

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 602036

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008780

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2362482

Country of ref document: CA

Ref document number: 2362482

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 33934/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020017011216

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000912160

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/991/KOL

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2000912160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017011216

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 36/2000 UNDER (81) ADD "AE, CR, DM, GD, IN, MA, TZ, ZA"

WWG Wipo information: grant in national office

Ref document number: 33934/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000912160

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011216

Country of ref document: KR